Skip to main content
Premium Trial:

Request an Annual Quote

Abingdon Health, BioSure UK Ink Manufacturing Deal for COVID-19 Lateral Flow Tests

NEW YORK ─ Rapid test developer Abingdon Health on Friday announced it has inked an exclusive manufacturing agreement with BioSure UK.

Under the terms of the agreement, York, UK-based Abingdon will manufacture BioSure’s COVID-19 lateral flow tests at Abingdon’s UK-based York and Doncaster sites.

Financial and other terms of the agreement were not disclosed.

Abingdon CEO Chris Yates said in a statement that the deal builds on its long-term collaboration with Essex, UK-based BioSure.

In March, the firms announced that they had inked a nonexclusive sales and distribution agreement for Abingdon's rapid SARS-CoV-2 neutralizing antibody test, AbC-19.